Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma

Inclusion Criteria:

* Histologically confirmed renal cell carcinoma in either primary or metastatic lesions. Non-clear histology will be allowed.
* Disease progression on a VEGF-targeted tyrosine kinase inhibitor as the most recent therapy or have experienced intolerable toxicity so as require discontinuation. Only one prior VEGF-targeted tyrosine kinase inhibitor.
* Must be off of VEGF-targeted tyrosine kinase inhibitor for 2 weeks or greater.
* One measurable lesion which is not curable by standard radiation therapy or surgery.
* The enrolling site must agree to obtain paraffin-embedded tumor blocks or at least 10 unstained, paraffin-embedded slides for submission for correlative studies.
* 18 years of age or older
* ECOG Performance Status of 0 or 1
* Baseline laboratory values as outlined in the protocol
* Life expectancy of greater than 3 months
* No prior malignancy diagnosed within the past three years, other than superficial basal cell and superficial squamous cell, or carcinoma in situ of the cervix.

Exclusion Criteria:

* Known CNS disease, except for treated brain metastases
* Previously treated with avastin or mTOR inhibitors
* Other then VEFG-targeted TKI, patients may only have had prior immunotherapy or chemotherapy for stage IV disease
* History of allergic reaction to Chinese hamster ovary cell products, other recombinant antibodies, or compounds of similar chemical or biologic composition to avastin or temsirolimus
* History of bleeding diathesis or coagulopathy. Therapeutic anticoagulants are allowed
* Patients with clinically significant cardiovascular disease
* Patients receiving enzyme-inducing antiepileptic drugs or any other CYP3A4 inducer such as rifampin or St. John's wort
* No serious non-healing wound, ulcer or bone fracture
* No uncontrolled intercurrent illness including , but not limited to, ongoing active infection requiring parental antibiotics or psychiatric illness/social situations that would limit compliance with study requirements
* HIV-positive receiving combination anti-retroviral therapy
* Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study enrollment or anticipation of need for major surgical procedure during the course of the study
* Core biopsy or other minor surgical procedure, excluding placement of vascular access device, within 7 days prior to enrollment on study
* History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to study enrollment
* Known hypersensitivity to any component of avastin or temsirolimus
* Life expectancy of less than 12 weeks
* History of hemoptysis within 1 month prior to day 1